Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-79635322 vs Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT07518186Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 18
01
Overview
Phase 3, randomised trial of ramantamig in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Complete Response or Better at 41 months and Progression-Free Survival at 41 months. Started May 2026; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07518186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518186.